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Introduction                                      
Peanut allergy is a major public health concern estimated to affect 
between 0.5-2% of children,1-3 and is one of the most common 
causes of food-related anaphylaxis.4 Peanut allergy usually begins 
early in life and tends to be persistent in at least 80% of cases.5 
There is no known “cure” for peanut allergy, though specific oral 
tolerance induction is being used to try and desensitise patients, 
but is in most cases not leading to permanent tolerance. Therefore, 
much attention has been paid recently to investigate strategies for 
the prevention of peanut allergy. Prevention of peanut allergy would 
have a significant impact on the individual as well as, potentially, 
at a public health level in view of recent evidence of an increase in 
peanut allergy in many parts of the world.2,4  
The LEAP study (Learning Early About Peanut Allergy), published in 
2015, was a pivotal trial in the realm of peanut allergy prevention.6 
This study enrolled 640 children at high risk of peanut allergy, which 
was defined, for this study, as infants between 4 and 11 months of 
age with severe eczema and/or egg allergy. At study entry, LEAP 
participants were stratified according to skin prick test (SPT) result to 
peanut into those with a negative SPT response (n = 530), a primary 
prevention group, and those with a measurable SPT response 
(1–4 mm), n = 98, a secondary prevention group as they were 
considered sensitised but not allergic to peanut at study entry. 
Participants with a SPT of greater than or equal to 5 mm were 
excluded because of their high risk of established peanut allergy. 
Patients were randomised to consume at least 2 grams of peanut 
protein thrice weekly or avoid peanut-containing food until 5 years 
of age, at which stage a peanut oral food challenge was performed. 
Results showed a significant reduction in peanut allergy in the early 
consumption group (Figure 1). 
Implications of the LEAP study and guidelines for the 
prevention of peanut allergy
The significant reduction in peanut allergy in the early consumption 
group led to international effort to develop practical clinical 
recommendations on peanut allergy prevention. A consensus 
statement regarding implementation of LEAP findings was published 
in 2015 on behalf of 9 international professional societies.8 In 
addition, the National Institute of Allergy and Infectious Diseases 
(NIAID) published addendum guidelines for the prevention of peanut 
allergy in the United States in 2017,9   an addendum to the 2010 
“Guidelines for the diagnosis and management of food allergy in the 
United States”. Recommendations for peanut introduction in infants 
are summarised in Table 1 and Figure 2 below. 
What amount of peanut protein should be given?
Based on the LEAP study, the first dose of peanut protein should be a 
cumulative dose of around 2 g of peanut protein (Table 2). Thereafter, 
the total minimum amount of peanut protein should be 6–7 g per 
week, consumed over 3 or more feedings per week.6,9  It is not yet 
known if other amounts and frequencies of ingesting peanut would 
have the same results.
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Figure 1: Summary of LEAP Study Outcomes6,7 
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Table 1: Recommendations for peanut introduction in infants according to risk stratification9
Infant criteria Recommendations Earliest age of peanut introduction
No eczema and no other food allergies Introduce peanut-containing foods In accordance with family preferences and cultural 
practices, but no need to delay beyond 6 months
Mild to moderate eczema Introduce peanut containing foods Around 6 months
Severe eczema,* egg allergy or both Evaluation by sIgE measurement and/or SPT, and if 
necessary, an OFC. Based on test results, introduce 
peanut-containing foods (see Figure 2 and Table 2)
Around 4–6 months
*Severe eczema defined as persistent or frequently recurring eczema with typical morphology and distribution assessed by a health care provider, requiring frequent need for prescription strength topical 
corticosteroids or calcineurin inhibitors despite appropriate use of emollients. 
Abbreviations: OFC: oral food challenge; sIgE: specific Immunoglobulin E; SPT: skin prick test
Figure 2: Peanut protein introduction in infants at high risk of peanut allergy7,9
Abbreviations: OFC: oral food challenge; sIgE: specific Immunoglobulin E; SPT: skin prick test
Severe eczema or egg 
allergy or both 
Peanut sIgE
< 0.35
Risk of reaction low: up to 
90% will have a negative 
SPT.
Options (based on 
provider/caregiver 
preference):
1. Introduce peanut at 
home
2. Doctor Supervised 
feeding in the office 
Risk of reaction low: 
95% will not have peanut 
allergy. 
Options (based on 
provider/caregiver 
preference):
1. Introduce peanut at 
home
2. Doctor Supervised 
feeding in the office 
Risk of reaction varies 
from moderate to high. 
Options are:
1. Doctor Supervised 
feeding in the office.
2. Graded OFC in a 
specialised facility
Infant probably allergic to 
peanut
Continue management by 
a specialist
Refer to specialist for 
consultation/ SPT protocol 
3-7 mm0-2 mm≥ 0.35 ≥8 mm
SPT Peanut
Table 2: Typical peanut containing foods and portion sizes7,9 
Food Typical serving containing 2 g of peanut protein Feeding tips
Peanut butter 8–10 g (2 teaspoons) Mix with warm water, breast milk or 
formula milk for a smoother texture. In 
older children, mix with pureed fruit or 
vegetables. 
Peanuts 8 g peanuts = approx. 10 whole peanuts or 
2½ teaspoons of ground peanuts 
(whole peanuts are a choking hazard in 
young children under the age of 3 years)
Add ground peanuts to a portion of 




Approximately 2 teaspoons 
Mix with yoghurt, apple sauce or 
apple juice. 
Bamba snack 17 g (2/3 of a 28 g packet or 21 sticks) For a smooth texture, mix with warm 
water/infant milk and mash well.
Reproduced with permission from reference 7.
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Case presentations
The following 3 cases demonstrate different scenarios and outcomes 
in infants at high risk of peanut allergy.
CASE 1
Background: Patient MB, a 7-month-old infant, presented with 
severe relapsing eczema since the age of 3 months. At 6 months, 
she developed an urticarial rash around the mouth after scrambled 
egg introduction. The infant was still being breastfed and selected 
solids, mainly fruits and vegetables, were being consumed. She had 
never eaten peanut before, and had not yet consumed cow’s milk 
products, soya, wheat or fish.
Examination revealed a well-nourished infant with diffuse moderately 
severe eczema. 
Skin prick test results (generally ≥ 3 mm is considered positive): 
Egg white 4 mm, fresh raw egg white 7 mm, peanut 2 mm. Cow’s 
milk, soya, hake fish, wheat: 0 mm.
Risk assessment: Results confirmed an IgE mediated egg 
allergy. Although this infant falls into the high risk category for the 
development of peanut allergy in view of eczema and egg allergy, 
the low skin prick test result of 2 mm was reassuring, though high 
enough to introduce the peanut under initial observation. 
Treatment Plan: An office based short peanut challenge was 
performed in 2 stages: 0.5 g peanut and then 1.5 g peanut protein 
(in the form of peanut butter) with observation for one hour.
Outcome: The peanut challenge was passed with no immediate 
reactions. The patient was advised to include peanut in the 
diet, around 2 g three times a week. Eczema and egg avoidance 
management was discussed. The mother was counselled to include 
other allergenic foods such as cow’s milk, fish and wheat in the 
infant’s diet. The infant was reassessed for eczema 2 weeks later 
and again 6 months later: the eczema improved and peanut was 
being consumed regularly with no reactions. 
Practice point:  In patients at high risk of peanut allergy, after initial 
assessment, peanut can be successfully introduced into the diet 
in many cases according to the “LEAP” recommendations, and a 
potential peanut allergy avoided. 
CASE 2
Background: Patient KD, a 5-month-old boy, presented with severe 
relapsing difficult-to-control eczema from 3 months of age. He was 
exclusively breastfed and not yet on any solids. Examination showed 
a well-grown infant with diffuse severe chronic eczema. 
Skin prick test results: Egg 3mm, fresh raw egg white 10 mm, 
cow’s milk 3 mm, fresh cow’s milk 7 mm. Peanut, soya, hake fish, 
wheat 0 mm.
Risk assessment: He was assessed as having a very high probability 
of egg and cow’s milk allergy. Although the patient fell into the high 
risk category for peanut allergy in view of severe eczema and egg 
allergy, the negative skin prick test was reassuring and expedited 
peanut introduction was encouraged.
Treatment Plan: Eczema, egg and cow’s milk avoidance 
management was discussed. Simple solid purees including fruits 
and vegetables were introduced. Two weeks later, an office based 
short peanut challenge was performed in 2 stages: 0.5 g peanut and 
1.5 g peanut with observation for one hour.
Outcome: The peanut challenge was passed. The patient was 
advised to include peanut in his diet, around 2 g three times a week. 
When he was reassessed for his eczema 1 month late, peanut was 
being consumed with no reactions. 
Further course: At 6 months, the patient unexpectedly reacted to 
cashew nut. Thereafter, he went through a fussy stage and refused 
regular peanut butter, resulting in no consumption of peanut products 
for 2 months. At 8 months of age, peanut was reintroduced and led 
to an urticarial rash around the mouth and vomiting. A skin prick test 
to peanut was repeated 2 weeks later: this time positive at 5 mm.
Practice point: The LEAP study protocol involved consumption of 
peanut at a minimum of 6–7 g per week for the first 5 years of 
life. Whilst it is not known if shorter periods or different amounts of 
ingestion would prevent allergy, cessation of consumption of peanut 
after initiation may result in the development of peanut allergy in 
some patients. Therefore, in patients at high risk of peanut allergy, 
if peanut consumption has been initiated, it should be encouraged 
on a regular basis. 
CASE 3
Background: Patient AM, a 6-month-old boy, had moderate to 
severe relapsing eczema from 3 months of age. He was still being 
breastfed and was also receiving some pureed vegetables. The 
mother was worried that the baby broke out in macular rashes when 
the she herself had consumed egg and dairy. 
Skin prick test results: Egg 3 mm, fresh raw egg white 5.5 mm, 
cow’s milk 5 mm, fresh cow’s milk 8 mm, peanut 3.5 mm. Soya, 
hake fish, wheat 0 mm.
Risk assessment: The infant was assessed as having a high 
probability of egg and cow’s milk allergy. The risk of peanut allergy 
was moderate to high based on the 3.5 mm positive SPT result.
Treatment Plan: Eczema management was discussed, and egg and 
cow’s milk avoidance implemented in both the mother and child. 
A formal peanut challenge was performed with 5 incremental doses 
of peanut butter, with a cumulative dose of 2.5 g peanut protein. The 
infant was observed for 2 hours after last peanut dose. 
Outcome: The peanut challenge was passed. The patient was 
advised to include peanut protein in the diet, around 2 g three times 
a week. 
Further course:  Three days later, when the mother gave the 
first home instalment of peanut butter, the patient reacted within 
15 minutes with urticaria around the mouth, followed 1 hour later by 
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profuse vomiting and a loose stool.  This settled with oral fluids and 
a quick-acting antihistamine. 
Practice point: Even in the LEAP study, some patients in the 
consumption group became allergic during the course of the study. 
Unfortunately, after the promising initial peanut challenge (which 
may have possibly represented a rapid desensitisation in this case), 
the patient presented with symptoms of a true peanut allergy, and 
peanut avoidance with regular follow-up was advised. 
Conclusion
The LEAP study6 provides level 1 evidence that healthcare providers 
should recommend introducing peanut-containing products into 
the diet of “high risk” infants (those with severe eczema and/
or egg allergy) early on in life, between 4 and 11 months of age. 
This is ideally done after evaluation by an allergist to assess the 
appropriateness of early peanut introduction and to help implement 
it practically. The dietitian is a key resource in guiding solids 
introduction and appropriate sources of certain allergens. Those with 
a low positive peanut skin prick test (3–7 mm) may benefit from 
an observed incremental peanut challenge. However, as the three 
presented cases demonstrate, peanut allergy cannot be prevented in 
all infants, and even in the early consumption group, up to 10% can 
develop a peanut allergy if they have a low positive skin prick test.6
The LEAP study6 included a high-risk population and cannot make 
recommendations on the benefit of early peanut introduction in 
the general or low-risk populations. In general, guidelines do not 
recommend delaying any major allergen’s introduction into the diet, 
even in the low-risk population. 
What is certain is that healthcare providers will need to be a major 
source of education and support for patients in order to implement 
early introduction of allergenic foods such as peanut. The opportunity 
should be taken at routine healthcare checks to identify the patient 
at risk of food allergy, and refer them in a timely fashion so that 
preventive strategies can be implemented early, where possible. 
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